Tissue Repair & Regenerative

BPC-157 (Body Protection Compound-157)

For Research Use Only. Not for Human or Veterinary Use.

Overview

BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a stable protein fragment found in gastric juice. It has been studied extensively in preclinical models of tissue repair — tendon and ligament healing, gastrointestinal-mucosa protection, wound healing and neuroprotection — and is notable among peptides for showing activity by the oral route in animal studies. It is a research compound; the evidence base is overwhelmingly preclinical.

Chemical Profile

PropertyValue
CAS number137525-51-2
ClassStable gastric pentadecapeptide
Amino-acid sequenceH-Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val-OH
One-letter codeGEPPPGKPADDAGLV
Molecular formulaC₆₂H₉₈N₁₆O₂₂
Molecular weight1419.52 g/mol
Purity (HPLC)≥ 98%
AppearanceWhite to off-white lyophilized powder
BPC-157 at a glance
Class
Stable gastric pentadecapeptide
Origin
Fragment of a human gastric-juice protein
Research status
Extensive preclinical investigation
Study routes
SC, oral, intraperitoneal, topical
Plasma half-life
≈ 15 min (active in tissues longer)
Key feature
Multi-tissue repair; notable oral activity

Mechanism of Action

BPC-157 is described in the literature as pleiotropic rather than acting on one receptor: it is studied for modulating the nitric-oxide (NO) system and angiogenic signalling at the same time, alongside effects on growth-factor expression and cell migration. This multi-pathway picture is why it appears across so many different tissue-repair models.

PathwayResearch description
AngiogenesisAssociated with upregulation of VEGF, VEGFR2, FGF and eNOS in repair models.
Nitric-oxide systemStudied for modulating NO production via the eNOS and nNOS pathways.
Growth factorsLinked to increased EGF, TGF-β and PDGF expression.
Cell migrationInvestigated through FAK and Src kinase signalling.
Anti-apoptotic tonePI3K/Akt activation and reduced caspase activity in models.
Anti-inflammatory toneDownregulation of TNF-α, IL-6 and IL-1β; upregulation of IL-10.

Tissue-specific effects reported in the literature (research context, not therapeutic claims):

TissueStudied mechanismReported direction
Tendon / ligamentFibroblast proliferation, collagen I synthesisFaster healing in models
GI mucosaImproved blood flow, prostaglandin signallingProtection vs NSAID-induced lesions (rodent)
MuscleMyoblast proliferation, reduced fibrosisImproved regeneration in models
Nervous systemNeurotrophic effects, reduced oxidative stressEnhanced neural recovery in models
SkinKeratinocyte migration, granulation tissueAccelerated wound closure in models

Pharmacology

ParameterValue
Half-life (t½)≈ 15 min in plasma; longer-lasting in tissues
Oral activityDemonstrated in animal models (unusual for a peptide)
Bioavailability (SC)≈ 40–60% (estimated)
Protein bindingModerate (albumin and tissue binding)
MetabolismProteolytic degradation (amino- / carboxypeptidases)
Route of administrationSC, oral, IP, topical (research settings)
EliminationRenal (peptide fragments)

Research Evidence

BPC-157 has a large preclinical (animal-model) literature and only very limited human data. The table names representative models and what they investigated; specific numerical outcomes are not restated here as claims.

ModelResearch focusReference
Rat Achilles-tendon transectionTendon functional recoverySikiric P, et al.
Rat NSAID-gastropathy modelGastric-mucosa protectionSikiric P, et al.
Rat / mouse skin-wound modelsWound closure and angiogenesisSeiwerth S, et al.
Rat spinal-cord / nerve modelsNeuroprotection and recoverySikiric P, et al.

Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):

Reported direction / findingContextReference
Faster tendon functional recovery vs controlsrat Achilles transectionSikiric P et al.
Protection against NSAID-induced gastric lesionsrat gastropathySikiric P et al.
Accelerated wound closure and angiogenesisrodent wound modelsSeiwerth S et al.

For laboratory research use only. Not for human or veterinary use, diagnosis, or therapeutic application. Descriptions refer to published research contexts and are not medical or product claims.

Dosing & Reconstitution Reference

Reconstitution and handling parameters for laboratory research. Not dosing guidance for human use.

ParameterReference value
Research dose range (literature)≈ 10–50 µg/kg daily (SC), in animal protocols
Reconstitution solventBacteriostatic water (0.9% benzyl alcohol)
Reconstitution volume1–2 mL per vial
Final concentration≈ 2.5–5 mg/mL
Storage (lyophilized)−20°C, protected from light
Storage (reconstituted)2–8°C, up to ~7 days
Do not useIf the solution is cloudy or contains particulates

Safety Profile

Published observations from research studies, provided for reference only. This material is not for human or veterinary use.

CategoryPublished observations
Local tolerabilityMild injection-site reactions reported
General tolerabilityWell tolerated in animal studies, including at high oral doses
CytotoxicityNo cytotoxicity observed in cell-based assays
GenotoxicityNegative Ames test in reported assays
InteractionsBecause it modulates the NO system, caution is noted around anticoagulants
StatusFor research use only; not for human or veterinary application

Physicochemical Properties

PropertyValue
Physical stateWhite to off-white lyophilized powder
Solubility (water)Freely soluble (> 50 mg/mL)
logP (octanol/water)≈ −2.8 (hydrophilic)
Isoelectric point (pI)≈ 4.2
pH (reconstituted)5.5–6.5
Stability (lyophilized)≥ 24 months at −20°C

Synthesis & Manufacturing

BPC-157 is produced by solid-phase peptide synthesis using Fmoc chemistry. As a 15-residue peptide with no unusual modifications, it is comparatively straightforward, with preparative HPLC bringing it to research-grade purity.

StepDetail
StrategyFmoc solid-phase peptide synthesis
ResinRink amide MBHA resin
CouplingHBTU / HOBt with DIPEA in DMF
Deprotection20% piperidine in DMF
CleavageTFA / TIPS / H₂O (95 : 2.5 : 2.5)
PurificationPreparative RP-HPLC (C18, TFA/ACN gradient)
  • Notes: coupling efficiency and complete Fmoc removal are monitored each cycle; hindered or repeated residues (e.g. Arg-Arg) may need double coupling.
  • Preparative RP-HPLC removes deletion and truncation impurities to reach research-grade purity; salt exchange (lyophilization from dilute HCl) removes residual TFA/acetate.
  • Critical quality attributes: correct molecular weight and low deletion-peptide content. No unusual residues; standard peptide QC applies.

Analytical Methods

MethodParameterTypical result
RP-HPLC (C18, UV 214 nm)Purity≥ 98%
HPLC retentionC18, 5–35% B over 25 minSingle main peak
ESI-MS (positive mode)Identity / mass[M+H]⁺ ≈ 1420 Da (charge +1 to +4)
MALDI-TOFMass confirmation[M+H]⁺ ≈ 1420 Da (charge +1 to +4)
Amino-acid analysisCompositionConsistent with the stated sequence
LC-MS (extracted ion)Deletion-peptide impuritiesWithin specification
Karl FischerWater content< 6%
LAL assayEndotoxinWithin specification
Ion chromatographyResidual TFA< 500 ppm

Representative RP-HPLC purity method:

  • Column: C18, 5 µm, 250 × 4.6 mm
  • Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
  • Gradient: 5–35% B over 25 min · Flow rate: 1.0 mL/min · Detection: UV 214 nm
  • Confirmatory LC-MS: ESI positive mode ([M+H]⁺ ≈ 1420 Da (charge +1 to +4)). No unusual residues; standard peptide QC applies.

Stability Data

Representative stability behaviour under common storage, handling and formulation conditions.

ConditionDurationResult
Lyophilized, −20°C, dark≥ 24 monthsNo significant degradation (purity > 97%)
Lyophilized, 2–8°C, dark≥ 12 monthsMinimal degradation (purity > 95%)
Lyophilized, 25°C (accelerated)3 months< 5% degradation
Reconstituted, 2–8°C, dark7–14 daysMinor degradation
Reconstituted, 25°C24–48 hUse promptly
Light exposure (ICH Q1B)1.2 M lux·hGenerally light-stable
Freeze–thaw (−20°C ⇄ 25°C)3 cyclesAcceptable — aliquot to avoid repeats
  • Keep lyophilized powder cold, dry and light-protected; keep any solution refrigerated and protected from light.
  • Minimise freeze-thaw cycles; aliquot material used across many sessions.
  • Key factor: No unusual residues; standard peptide QC applies.

Selected References

  • Sikiric P, et al. Stable gastric pentadecapeptide BPC-157: a review of the studies on its healing effects. (review literature).
  • Seiwerth S, et al. BPC-157 and blood-vessel / wound-healing research. (preclinical literature).
  • Chang CH, et al. The promoting effect of BPC-157 on tendon fibroblasts and tendon healing. (preclinical literature).

Quality & Supply

  • HPLC ≥ 98% purity with a Certificate of Analysis per batch
  • Identity confirmed by LC-MS
  • Research samples through to bulk, with worldwide delivery
  • Custom quantities and packaging on request

Need BPC-157 — sample or bulk?

HPLC-verified, COA per batch. Tell us the quantity you need.

Request a Quote